Exenatide
approvedAlso known as: Byetta, Bydureon, Exendin-4
**Mechanism of Action** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster (*Heloderma suspectum*). It acts as a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor, a class B G-protein-coupled receptor. By mimicking endogenous incretin hormones, exenatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and promotes satiety. Its resistance to dipeptidyl peptidase-4 (DPP-4) degradation confers a prolonged half-life relative to native GLP-1. **Key Research Findings** Clinical trials have demonstrated that exenatide significantly reduces fasting and postprandial glucose levels, lowers glycated hemoglobin (HbA1c) by approximately 0.8–1.5%, and promotes modest weight loss (2–5 kg) in patients with type 2 diabetes. Long-term studies (e.g., the EXSCEL trial) have shown cardiovascular safety, with a neutral effect on major adverse cardiac events. Preclinical and observational data also suggest potential benefits on beta-cell proliferation and survival, though these findings remain under investigation. Common adverse effects include transient nausea and vomiting, with rare reports of pancreatitis and thyroid C-cell hyperplasia. **Clinical Relevance** Approved by the FDA in 2005 (Byetta, twice-daily) and 2012 (Bydureon, once-weekly), exenatide is indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. It is often used when metformin or sulfonylureas are insufficient, and its weight-neutral or weight-reducing profile offers an advantage over insulin or sulfonylureas. Exenatide is contraindicated in patients with severe renal impairment or a personal/family history of medullary thyroid carcinoma. For research purposes only — not medical advice.
Key data
C184H282N50O60SResearch & studies
Exenatide group lost 0.5 kg (-0.6%) while placebo group gained 2.6 kg (+2.8%) (both p < .01).; Common side effects with exenatide were gastrointestinal symptoms and headaches.; No clinically meaningful changes in mood or psychotic symptoms between groups.; Exenatide was effective and well-tolerated for attenuating olanzapine-associated weight gain.
Exenatide was more effective than placebo in participants smoking >20 cigarettes per day (PP = 81.7%).; Greater exenatide benefit was observed in participants without prediabetes (PP = 76.0%) and without obesity (PP = 94.4%).; Exenatide efficacy was limited to individuals with no/minimal depression symptoms (PP = 91.2%).; Exenatide was more efficacious only in those with the CHRNA rs16969968 GG genotype (PP = 88.6%).
Acute exenatide pretreatment did not change cocaine self-administration or subjective effects (euphoria, wanting).; Exenatide reduced GLP-1 and insulin levels compared to placebo.; Self-administered cocaine reduced GLP-1, insulin, and amylin levels.; Study limitations include single acute dose and lack of chronic pretreatment.
Frequently asked questions
What is Exenatide?
**Mechanism of Action** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster (*Heloderma suspectum*). It acts as a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor, a class B G-protein-coupled receptor. By mimicking endogenous incret
How does Exenatide work?
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
What is the research status of Exenatide?
Exenatide is currently classified as approved, with 2,823 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Exenatide?
The reported half-life of Exenatide is ~2.4 hours.
What is the molecular weight of Exenatide?
Exenatide has a molecular weight of approximately 4187 g/mol (formula C184H282N50O60S).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Exenatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key